var data={"title":"Ampicillin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ampicillin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5637?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ampicillin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ampicillin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ampicillin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134956\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ampicillin for Injection;</li>\n      <li>Apo-Ampi;</li>\n      <li>Novo-Ampicillin;</li>\n      <li>Nu-Ampi</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135006\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Penicillin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134960\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 250 to 500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV: 1 to 2 g every 4 to 6 hours or 50 to 250 mg/kg/day in divided doses (maximum: 12 g/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, treatment (off-label dose; AHA [Baddour 2015]):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Enterococcus, native or prosthetic valve (penicillin/gentamicin-susceptible strains):</i> 2 g every 4 hours with concomitant ceftriaxone for 6 weeks <b>or</b> 2 g every 4 hours with concomitant gentamicin for 4 to 6 weeks (4 weeks for native valve <b>and</b> symptoms present &lt;3 months; 6 weeks for native valve <b>and</b> symptoms present &ge;3 months <b>or</b> for prosthetic valve)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Enterococcus, native or prosthetic valve (penicillin-susceptible/aminoglycoside-resistant strains):</i> 2 g every 4 hours with concomitant ceftriaxone for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Enterococcus, native or prosthetic valve (penicillin-susceptible/gentamicin-resistant/streptomycin-susceptible strains):</i> 2 g every 4 hours with concomitant streptomycin for 4 to 6 weeks (4 weeks for native valve <b>and</b> symptoms present &lt;3 months; &ge;6 weeks for native valve <b>and</b> symptoms present &ge;3 months or prosthetic valve).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HACEK organisms, native or prosthetic valve (off-label use):</i> 2 g every 4 hours for 4 weeks (native valve) or 6 weeks (prosthetic valve).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Viridans group streptococcus (VGS) and S. bovis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Native valve:</i> Highly penicillin-susceptible (MIC &le;0.12 mcg/mL): 2 g every 4 hours for 4 weeks (monotherapy) or for 2 weeks with concomitant gentamicin</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Native valve:</i> Relatively penicillin-resistant (MIC &gt;0.12 to &lt;0.5 mcg/mL): 2 g every 4 hours for 4 weeks with concomitant gentamicin for the first 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prosthetic valve:</i> Highly penicillin-susceptible (MIC &le;0.12 mcg/mL): 2 g every 4 hours for 6 weeks (with or without concomitant gentamicin for the first 2 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prosthetic valve:</i> Relatively or fully penicillin-resistant (MIC &gt;0.12 mcg/mL): 2 g every 4 hours with concomitant gentamicin for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, prophylaxis (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dental, oral, or respiratory tract procedures:</i> IM, IV: 2 g within 30 to 60 minutes prior to procedure in patients not allergic to penicillin and unable to take oral amoxicillin. IM injections should be avoided in patients who are receiving anticoagulant therapy. In these circumstances, orally administered regimens should be given whenever possible. Intravenously administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications. <b>Note:</b> American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur (Wilson 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Genitourinary and gastrointestinal tract procedures:</i> IM, IV: <b>Note:</b> Routine prophylaxis for GI/GU procedures is no longer recommended by the AHA. Consider only in patients with the highest risk of adverse outcome from endocarditis (eg, prosthetic heart valve, previous endocarditis, some categories of congenital heart disease, cardiac valvulopathy in cardiac transplant patients) who have an established GI or GU enterococcal infection or for those already receiving antibiotic therapy to prevent a wound infection or sepsis associated with a GI or GU procedure in which enterococcal coverage is desired (Wilson 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High-risk patients: 2 g within 30 minutes prior to procedure, followed by ampicillin 1 g (or amoxicillin 1 g orally) 6 hours later; must be used in combination with gentamicin (Dajani 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate-risk patients: 2 g within 30 minutes prior to procedure (Dajani 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Genitourinary or gastrointestinal infections:</b> Oral, IM, IV: 500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b> Group B streptococcus (maternal dose for neonatal prophylaxis) (off-label use):</b> IV: 2 g initial dose, then 1 g every 4 hours until delivery (CDC 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Listeria </i></b>  <b>infections (off-label dosing; Lorber, 1997):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bacteremia: 200 mg/kg/day divided every 6 hours for &ge;2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Brain abscess or rhombencephalitis: 200 mg/kg/day divided every 4 hours with concomitant aminoglycoside for &ge;6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocarditis: 200 mg/kg/day divided every 6 hours with concomitant aminoglycoside for &ge;4 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Meningitis: 200 mg/kg/day divided every 4 hours with concomitant aminoglycoside for &ge;3 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mild to moderate infections:</b> Oral: 250 to 500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteomyelitis, native vertebral (off-label use):</b> <i>Enterococcus</i> spp (penicillin-susceptible): IV: 12 g continuous infusion every 24 hours <b>or</b> 2 g every 4 hours for 6 weeks; the addition of an aminoglycoside for 4 to 6 weeks is recommended in patients with infective endocarditis (IDSA [Berbari 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prosthetic joint infection, <b><i>Enterococcus</i></b> spp (penicillin-susceptible) (off-label use):</b> IV: 12 g continuous infusion every 24 hours <b>or</b> 2 g every 4 hours for 4 to 6 weeks; consider addition of aminoglycoside (Osmon, 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis in total joint replacement patients undergoing dental procedures which produce bacteremia (off-label use): Note:</b> In general, patients with prosthetic joint implants do not require prophylactic antibiotics prior to dental procedures. In planning an invasive oral procedure, dental consultation with the patient's orthopedic surgeon may be advised to review the risks of infection (Sollecito 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV: 2 g 1 hour prior to procedure (ADA/AAOS 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Respiratory tract infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 250 mg 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV: 250 to 500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sepsis/meningitis:</b> IM, IV: <b>Note: </b>administer doses IV initially; IM may be used later in therapy course: 150 to 200 mg/kg/day divided every 3 to 4 hours (range: 6 to 12 g/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (perioperative) prophylaxis in liver transplantation (off-label use):</b> IV: 2 g within 60 minutes prior to surgery in combination with cefotaxime. Doses may be repeated in 2 hours if procedure is lengthy or if there is excessive blood loss (Bratzler, 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infections (ampicillin-susceptible <i>Enterococcus</i>; off-label use):</b> IV: 1 to 2 g every 4 to 6 hours with or without an aminoglycoside (Heintz 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134982\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ampicillin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 50 to 100 mg/kg/day divided every 6 hours (maximum: 2 to 4 g/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV: 25 to 200 mg/kg/day divided every 3 to 4 hours (maximum: 12 g/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Community-acquired pneumonia (CAP) (IDSA/PIDS 2011):</b> Infants &gt;3 months, Children, and Adolescents: IV: <b>Note:</b> May consider addition of vancomycin or clindamycin to empiric therapy if community-acquired MRSA suspected. In children &ge;5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out. Maximum daily dose of ampicillin: 12 g/day (<i>Red Book</i> [AAP 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Empiric treatment or <i>S. pneumoniae</i> (moderate to severe; MICs to penicillin &le;2.0 mcg/mL) or <i>H. influenzae</i> (beta-lactamase negative) (preferred): 150 to 200 mg/kg/day divided every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Group A <i>Streptococcus </i> (moderate to severe) (preferred): 200 mg/kg/day divided every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>S. pneumoniae</i> (moderate to severe; MICs to penicillin &ge;4.0 mcg/mL) (alternative to ceftriaxone): 300 to 400 mg/kg/day divided every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, prophylaxis (off-label use):</b> <b> Note: </b>AHA guidelines (Baltimore 2015) limit the use of prophylactic antibiotics to patients at the highest risk for infective endocarditis (IE) or adverse outcomes (eg, prosthetic heart valves, patients with previous IE, unrepaired cyanotic congenital heart disease, repaired congenital heart disease with prosthetic material or device during first 6 months after procedure, repaired congenital heart disease with residual defects at the site or adjacent to site of prosthetic patch or device, and heart transplant recipients with cardiac valvulopathy):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dental, oral, or respiratory tract procedures </i>\n      <i>(eg, tonsillectomy, adenoidectomy)<i>:</i></i> Infants, Children, and Adolescents: IM, IV: 50 mg/kg within 30 to 60 minutes before procedure; maximum dose: 2,000 mg/dose. IM injections should be avoided in patients who are receiving anticoagulant therapy. In these circumstances, orally administered regimens should be given whenever possible. Intravenously administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications (Wilson 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis treatment (off-label): </b>Children and Adolescents: IV: 200 to 300 mg/kg/day divided every 4 to 6 hours; maximum daily dose: 12 g/<b>day</b>; use in combination with other antibiotics for at least 4 weeks; some organisms may require longer duration (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Genitourinary or gastrointestinal infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &le;20 kg: 100 mg/kg/day in divided doses 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &gt;20 kg: 500 mg 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;40 kg: 50 mg/kg/day in divided doses every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &ge;40 kg: 500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mild to moderate infections:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 50 to 100 mg/kg/day divided every 6 hours (maximum: 2 to 4 g/day) (<i>Red Book</i> [AAP 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV: 100 to 150 mg/kg/day divided every 6 hours (maximum: 2 to 4 g/day) (<i>Red Book</i> [AAP 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Respiratory tract infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &le;20 kg: 50 mg/kg/day in divided doses 3 to 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &gt;20 kg: 250 mg 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;40 kg: 25 to 50 mg/kg/day in divided doses every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &ge;40 kg: 250 to 500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe infections, meningitis, septicemia:</b> Infants, Children, and Adolescents: IM, IV: <b>Note:</b> Treatment should be initiated with IV infusion therapy and may be continued with IM injections if preferred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling:</i> 150 to 200 mg/kg/day in divided doses every 3 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative recommendation:</i> 200 to 400 mg/kg/day in divided doses every 6 hours (maximum: 6 to 12 g/day) (<i>Red Book </i>[AAP 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (perioperative) prophylaxis in liver transplantation (off-label use):</b> Children &ge;1 year: IV: 50 mg/kg within 60 minutes prior to surgery (maximum: 2,000 mg/dose) in combination with cefotaxime. Doses may be repeated in 2 hours if procedure is lengthy or if there is excessive blood loss (Bratzler 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134961\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134962\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, the following adjustments have been recommended (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;50 mL/minute: Administer every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 50 mL/minute: Administer every 6 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute: Administer every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (20% to 50%): IV: 1 to 2 g every 12 to 24 hours (administer after hemodialysis on dialysis days) (Heintz 2009). <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis (PD): IV: 250 mg every 12 hours (Aronoff, 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT) (Heintz, 2009): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVH: Loading dose of 2 g followed by 1 to 2 g every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVHD: Loading dose of 2 g followed by 1 to 2 g every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVHDF: Loading dose of 2 g followed by 1 to 2 g every 6 to 8 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673180\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134931\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg [DSC], 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as sodium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg (1 ea); 250 mg (1 ea); 500 mg (1 ea); 1 g (1 ea); 2 g (1 ea); 10 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as sodium [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg (1 ea); 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sodium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea); 10 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sodium [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg/5 mL (100 mL [DSC], 200 mL [DSC]); 250 mg/5 mL (100 mL [DSC], 200 mL [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134915\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134935\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer around-the-clock to promote less variation in peak and trough serum levels. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Oral: Administer on an empty stomach with a full glass (8 oz) of water (ie, 30 minutes prior to or 2 hours after meals) to increase total absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">IM.: Inject deep IM into a large muscle mass</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Direct IV bolus: Administer over 3 to 5 minutes (125 to 500 mg) or over 10 to 15 minutes (1 to 2 g). More rapid infusion may cause seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infusion: Rapid infusion may cause seizures. Adjust rate of infusion so that the total dose is administered before admixture stability expires.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134934\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Genitourinary tract infections:</b> Treatment of genitourinary tract infections caused by <i>Escherichia coli</i>, <i>Proteus mirabilis</i>, enterococci, <i>Shigella</i>, <i>Salmonella typhosa</i> and other <i>Salmonella</i>, and nonpenicillinase-producing <i>N. gonorrhoeae</i>. <b>Note:</b> Ampicillin is <b>not</b> recommended by the CDC as a first-line agent in the treatment of gonorrhea (CDC, 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>GI tract infections:</b> Treatment of GI tract infections caused by <i>Shigella</i>, <i>S. typhosa</i> and other <i>Salmonella</i>, <i>E. coli</i>, <i>P. mirabilis</i>, and enterococci. <b>Note:</b> Ampicillin is not recommended as a first-line agent for Shigellosis, Salmonellosis (nontyphoid), or <i>Salmonella enterica</i> species (typhoid fever) due to development of resistance (CDC, 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Respiratory tract infections:</b> Treatment of respiratory tract infections caused by nonpenicillinase-producing <i>H. influenzae</i> and staphylococci, and streptococci, including <i>Streptococcus pneumoniae</i>.</p>\n    <p style=\"text-indent:0em;\">Injection:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacterial meningitis:</b> Treatment of bacterial meningitis caused by <i>E. coli</i>, group B streptococci, and other gram-negative bacteria (<i>N. meningitidis</i>).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastrointestinal infections:</b> Treatment of GI infections caused by <i>S. typhi</i> (typhoid fever), other <i>Salmonella</i> species and <i>Shigella</i> species (dysentery). <b>Note:</b> Ampicillin is <b>not</b> recommended as a first-line agent for Shigellosis, Salmonellosis (nontyphoid), or <i>S. enterica</i> species (typhoid fever) due to development of resistance (CDC, 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Respiratory tract infections:</b> Treatment of respiratory tract infections caused by <i>S. pneumoniae</i>, <i>Staphylococcus aureus</i> (penicillinase and nonpenicillinase producing), <i>H. influenzae</i>, and group A beta-hemolytic streptococci.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Septicemia and endocarditis:</b> Treatment of septicemia and endocarditis caused by susceptible gram-positive organisms, including Streptococcus species, penicillin G-susceptible staphylococci, and enterococci; gram-negative sepsis caused by <i>E. coli</i>, <i>P. mirabilis</i>, and <i>Salmonella</i> species.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infections: </b>Treatment of urinary tract infections caused by <i>E. coli</i> and <i>P. mirabilis</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475066\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Community-acquired pneumonia (children); Endocarditis, prophylaxis; Endocarditis, treatment (HACEK organisms) (adults); Osteomyelitis, native vertebral; Prophylaxis in patients with prosthetic joint implants undergoing dental procedures which produce bacteremia; Prosthetic joint infection; Surgical prophylaxis (liver transplantation); Group B streptococcus (maternal dose for neonatal prophylaxis); Urinary tract infection due to ampicillin-susceptible Enterococcus spp.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135014\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ampicillin may be confused with aminophylline</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134922\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Brain disease (penicillin-induced), glossalgia, seizure, sore mouth</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema multiforme, exfoliative dermatitis, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Appearance of a rash should be carefully evaluated to differentiate (if possible) nonallergic ampicillin rash from hypersensitivity reaction. Incidence is higher in patients with viral infection, <i>Salmonella</i> infection, lymphocytic leukemia, or patients that have hyperuricemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, enterocolitis, glossitis, melanoglossia, nausea, oral candidiasis, pseudomembranous colitis, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, anemia, eosinophilia, hemolytic anemia, immune thrombocytopenia, leukopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Serum sickness-like reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Interstitial nephritis (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Stridor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Dysgeusia (Syed 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134938\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, anaphylaxis) to ampicillin, any component of the formulation, or other penicillins; infections caused by penicillinase-producing organisms </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134919\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity/anaphylactoid reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity or a history of sensitivity to multiple allergens. Serious anaphylactoid reactions require emergency treatment and airway management.  Appropriate treatments must be readily available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Rash: Appearance of a rash should be carefully evaluated to differentiate a nonallergic ampicillin rash from a hypersensitivity reaction; rash occurs in 5% to 10% of children and is a generalized dull red, maculopapular rash, generally appearing 3 to 14 days after the start of therapy. It normally begins on the trunk and spreads over most of the body. It may be most intense at pressure areas, elbows, and knees. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>Clostridium difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infectious mononucleosis: A high percentage of patients with infectious mononucleosis have developed rash during therapy; ampicillin-class antibiotics not recommended in these patients. Rash (generalized maculopapular and pruritic) usually appears 7 to 10 days after initiation and usually resolves within a week of discontinuation. It is not known whether these patients are truly allergic to ampicillin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298748\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134924\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8737&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May enhance the potential for allergic or hypersensitivity reactions to Ampicillin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atenolol: Ampicillin may decrease the bioavailability of Atenolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroquine: May decrease the serum concentration of Ampicillin. Management: Chloroquine prescribing information recommends separating administration of ampicillin and chloroquine by at least 2 hours to minimize any potential negative impact of chloroquine on ampicillin bioavailability.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Ampicillin. Management: Administer oral ampicillin at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134951\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food decreases ampicillin absorption rate; may decrease ampicillin serum concentration. Management: Take at equal intervals around-the-clock, preferably on an empty stomach (30 minutes before or 2 hours after meals). Maintain adequate hydration, unless instructed to restrict fluid intake.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134927\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134941\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Ampicillin crosses the placenta, providing detectable concentrations in the cord serum and amniotic fluid (Bolognese 1968; Fisher 1967; MacAulay 1966). Maternal use of ampicillin has generally not resulted in an increased risk of birth defects (Aselton 1985; Czeizel 2001b; Heinonen 1977; Jick 1981; Puh&oacute; 2007). Ampicillin is recommended for use in pregnant women for the management of preterm prelabor rupture of membranes (PROM) and for the prevention of early-onset group B streptococcal (GBS) disease in newborns. Ampicillin may also be used in certain situations prior to vaginal delivery in women at high risk for endocarditis (ACOG 120 2011; ACOG 188 2018; ACOG 485 2011; CDC [RR-10] 2010).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The volume of distribution of ampicillin is increased during pregnancy and the half-life is decreased. As a result, serum concentrations in pregnant patients are approximately 50% of those in nonpregnant patients receiving the same dose. Higher doses may be needed during pregnancy. Although oral absorption is not altered during pregnancy, oral ampicillin is poorly absorbed during labor (Philipson 1977; Philipson 1978; Wasz-H&ouml;ckert 1970).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5673664\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ampicillin is present in breast milk. The manufacturer recommends that caution be exercised when administering ampicillin to breastfeeding women. Due to the low concentrations in human milk, minimal toxicity would be expected in the breastfed infant. Nondose-related effects could include modification of bowel flora and allergic sensitization.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134942\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Take on an empty stomach 30 minutes before or 2 hours after meals. Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134929\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">With prolonged therapy, monitor renal, hepatic, and hematologic function periodically; observe signs and symptoms of anaphylaxis during first dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134918\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134937\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: 50% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Into bile; penetration into CSF occurs with inflamed meninges only</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Neonates: 10%; Adults: 15% to 18% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 2 to 7 days: 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 8 to 14 days: 2.8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 15 to 30 days: 1.7 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adults: 1 to 1.8 hours (Bergan 1979)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anuric patients: 8 to 20 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak serum concentration: Oral: Within 1 to 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&sim;90%, unchanged within 24 hours); feces </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422187\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Ampicillin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $58.89</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Ampicillin Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $7.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $13.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $84.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (1): $5.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (1): $2.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $3.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Ampicillin Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $16.37</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $8.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $84.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134943\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acipillin (BD);</li>\n      <li>Alphacin (NZ);</li>\n      <li>Alphapen (MX);</li>\n      <li>Ambiopi (ID);</li>\n      <li>Amcillin (KR);</li>\n      <li>Amcopen (PK);</li>\n      <li>Amfipen (AE, BH, CY, EG, GB, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Amicap (BD);</li>\n      <li>Amillin (MY);</li>\n      <li>Amipenix (JP);</li>\n      <li>Ampecu (EC);</li>\n      <li>Ampen (VE);</li>\n      <li>Ampi-1 (PH);</li>\n      <li>Ampibex (EC);</li>\n      <li>Ampiblan (CO);</li>\n      <li>Ampicil (BR);</li>\n      <li>Ampicilin (ET);</li>\n      <li>Ampicilina (EC);</li>\n      <li>Ampicillin (PL);</li>\n      <li>Ampicin (PH);</li>\n      <li>Ampiclin (PH);</li>\n      <li>Ampiclox (SG);</li>\n      <li>Ampicyn (AU, TH);</li>\n      <li>Ampidar (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ampiger (BR);</li>\n      <li>Ampilag (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Ampilin (IN);</li>\n      <li>Ampillin (MY);</li>\n      <li>Ampimedin (PY);</li>\n      <li>Ampina (LK);</li>\n      <li>Ampipen (IN, ZA);</li>\n      <li>Ampipharm (JO);</li>\n      <li>Ampitenk (AR);</li>\n      <li>Ampitrex (PH);</li>\n      <li>Ampivral (CO);</li>\n      <li>Ampliblan (CO);</li>\n      <li>Ampolin (TW);</li>\n      <li>Amsapen (MX);</li>\n      <li>Ancillin (TW);</li>\n      <li>Antallpen (LB);</li>\n      <li>Ascillin (ET);</li>\n      <li>Austrapen (AU);</li>\n      <li>Axum (HU);</li>\n      <li>Binotal (AT, BR, CO, MX, UY);</li>\n      <li>Biocil (MY);</li>\n      <li>Bridopen (PH);</li>\n      <li>Britapen (ES);</li>\n      <li>Brupen (MX);</li>\n      <li>Camicil (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Dancin (PH);</li>\n      <li>Dhacillin (MY);</li>\n      <li>Dibacilina (MX);</li>\n      <li>Dinpen (PH);</li>\n      <li>Doktacillin (SE);</li>\n      <li>Duacillin (MY);</li>\n      <li>Eurocin (PH);</li>\n      <li>Excillin (PH);</li>\n      <li>Extrapen (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Ficillin (BD);</li>\n      <li>Flamicina (MX);</li>\n      <li>Gobemicina (ES);</li>\n      <li>Gobemicina Retard (CR, DO, HN, NI, PA, SV);</li>\n      <li>Gramcil (PH);</li>\n      <li>Ibimycin (AU);</li>\n      <li>Intramed (ZA);</li>\n      <li>Iwacillin (JP);</li>\n      <li>Maeline (LK);</li>\n      <li>Magnapen (PE);</li>\n      <li>Marovilina (MX);</li>\n      <li>Maxipen (CO);</li>\n      <li>Meprizna (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Microcilin (PH);</li>\n      <li>Nimpicillin (LK);</li>\n      <li>Norcipen (JO);</li>\n      <li>Novencil (EC);</li>\n      <li>Omnipen (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, MX, OM, QA, SA, SY, YE);</li>\n      <li>Pamecil (BF, BJ, CI, ET, GH, GM, GN, JO, KE, LR, LV, MA, ML, MR, MU, MW, MY, NE, NG, RO, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Panacta (PH);</li>\n      <li>Pelitin (TW);</li>\n      <li>Penbrex (KR);</li>\n      <li>Penbritin (AE, BF, BH, BJ, CI, CR, CY, DO, EG, ET, GH, GM, GN, GT, HN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, OM, PA, PE, QA, SA, SC, SD, SL, SN, SV, SY, TN, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Penibrin (IL);</li>\n      <li>Penodil (TR);</li>\n      <li>Pentrexyl (BE, BF, BJ, CI, DK, ET, GB, GH, GM, GN, GR, IT, KE, LR, LU, MA, ML, MR, MU, MW, MX, NE, NG, NO, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Petercillin (ZA);</li>\n      <li>Polypen (PH);</li>\n      <li>Primapen (ID);</li>\n      <li>Promecilina (MX);</li>\n      <li>Pulmosterin Retard (CR, DO, HN, NI, PA, SV);</li>\n      <li>Radiocillina (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Reichlin (HK);</li>\n      <li>Rimacillin (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PR, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW);</li>\n      <li>Roscillin (IN, LK);</li>\n      <li>Sanpicillin (ID);</li>\n      <li>Semicillin (HN, HU);</li>\n      <li>Shacillin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Silina (ET);</li>\n      <li>Standacillin (AE, AT, BG, BH, CY, EE, EG, HU, IQ, IR, JO, KW, LB, LY, OM, QA, RO, SA, SY, YE);</li>\n      <li>Standcillin (MY);</li>\n      <li>Synthocilin (IN);</li>\n      <li>Syntocil (TR);</li>\n      <li>Totapen (FR);</li>\n      <li>Tricil (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Trifalicina (AR);</li>\n      <li>Trilaxin (PH);</li>\n      <li>Ultracillin (AE);</li>\n      <li>Viccillin (ID, TH);</li>\n      <li>Vidopen (GB);</li>\n      <li>Virucil (CO);</li>\n      <li>Winpicillin (TW);</li>\n      <li>Z-Cil (ET);</li>\n      <li>Zampicillin (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, &quot;ACOG Practice Bulletin No. 120: Use of Prophylactic Antibiotics in Labor and Delivery,&quot; <i>Obstet Gynecol</i>, 2011, 117(6):1472-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/21606770/pubmed\" target=\"_blank\" id=\"21606770\">21606770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists Committee on Obstetric Practice. ACOG Practice Bulletin No. 188: prelabor rupture of membranes. <i>Obstet Gynecol</i>. 2018;131(1):e1-e14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/29266075/pubmed\" target=\"_blank\" id=\"29266075\">29266075</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists Committee on Obstetric Practice, &quot;ACOG Committee Opinion No. 485: Prevention of Early-Onset Group B Streptococcal Disease in Newborns,&quot; <i>Obstet Gynecol</i>, 2011, 117(4):1019-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/21422882/pubmed\" target=\"_blank\" id=\"21422882\">21422882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12892448\"></a>American Dental Association (ADA); American Academy of Orthopedic Surgeons (AAOS). Antibiotic prophylaxis for dental patients with total joint replacements. <i>J Am Dent Assoc</i>. 2003;134(7):895-899.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/12892448/pubmed\" target=\"_blank\" id=\"12892448\">12892448</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ampicillin injection [prescribing information]. Lake Forest, IL: Hospira; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aselton P, Jick H, Milunsky A, et al, &quot;First-Trimester Drug Use and Congenital Disorders,&quot; <i>Obstet Gynecol</i>, 1985, 65(4):451-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/3982720/pubmed\" target=\"_blank\" id=\"3982720\">3982720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015;132(17):e215]. <i>Circulation</i>. 2015;132(15):1435-1486.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/26373316/pubmed\" target=\"_blank\" id=\"26373316\">26373316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/26229122/pubmed\" target=\"_blank\" id=\"26229122\">26229122</a>]</span><span class=\"doi\">10.1093/cid/civ482</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bergan T. Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin. <i>Antimicrob Agents Chemother</i>. 1978;13(6):971-974.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/677863 /pubmed\" target=\"_blank\" id=\"677863 \">677863 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boguniewicz M and Leung DY, &ldquo;Hypersensitivity Reactions to Antibiotics Commonly Used in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1995, 14(3):221-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/7761188/pubmed\" target=\"_blank\" id=\"7761188\">7761188</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bolognese RJ, &quot;Ampicillin: Transfer Into Fetus and Amniotic Fluid,&quot; <i>Rocky Mt Med J</i>, 1968, 65(8):72-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/5667909/pubmed\" target=\"_blank\" id=\"5667909\">5667909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown RD and Campoli-Richards DM, &ldquo;Antimicrobial Therapy in Neonates, Infants, and Children,&rdquo; <i>Clin Pharmacokinet</i>, 1989, 17(Suppl 1):105-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/2692934/pubmed\" target=\"_blank\" id=\"2692934\">2692934</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Prevention of Perinatal Group B Streptococcal Disease-Revised Guidelines From CDC, 2010,&quot; <i>MMWR Recomm Rep</i>, 2010, 59(RR-10):1-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/21088663/pubmed\" target=\"_blank\" id=\"21088663\">21088663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow MS, Quintiliani R, and Nightingale CH, &quot;<i>In Vivo</i> Inactivation of Tobramycin by Ticarcillin. A Case Report,&quot; <i>JAMA</i>, 1982, 247(5):658-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/6798229/pubmed\" target=\"_blank\" id=\"6798229\">6798229</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Czeizel AE, Rockenbauer M, S&oslash;rensen HT, et al, &quot;A Population-Based Case-Control Teratologic Study of Ampicillin Treatment During Pregnancy,&quot; <i>Am J Obstet Gynecol</i>, 2001b, 185(1):140-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/11483918/pubmed\" target=\"_blank\" id=\"11483918\">11483918</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dajani AS, Taubert KA, Wilson W, et al, &ldquo;Prevention of Bacterial Endocarditis Recommendations by the American Heart Association,&rdquo; <i>JAMA</i>, 1997, 277(22):1794-801.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/9178793/pubmed\" target=\"_blank\" id=\"9178793\">9178793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daly JS, Dodge RA, Glew RH, et al, &quot;Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages,&quot; <i>J Perinatol</i>, 1997, 17(1):42-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/9069064/pubmed\" target=\"_blank\" id=\"9069064\">9069064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo; <i>N Engl J Med</i>, 1988, 318(7):419-26 and 318(8):490-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/3277054/pubmed\" target=\"_blank\" id=\"3277054\">3277054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell JA, Korth-Bradley J, Milisci M, et al, &quot;Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment,&quot; <i>J Clin Pharmacol</i>, 2001, 41:979-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/11549103/pubmed\" target=\"_blank\" id=\"11549103\">11549103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farchione LA, &quot;Inactivation of Aminoglycosides by Penicillins,&quot; <i>J Antimicrob Chemother</i>, 1982, 8(Suppl A):27-36.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fisher AM and Smith MR, &quot;The Prophylactic Use of Ampicillin and Its Trans-Placental Passage After Amniotomy,&quot; <i>J Obstet Gynaecol Br Commonw</i>, 1967, 74(6):855-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/6066463/pubmed\" target=\"_blank\" id=\"6066463\">6066463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuchs PC, Stickel S, Anderson PH, et al, &quot;<i>In Vitro</i> Inactivation of Aminoglycosides by Sulbactam, Other Beta-Lactams, and Sulbactam-Beta-Lactam Combinations,&quot; <i>Antimicrob Agents Chemother</i>, 1991, 35(1):182-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/2014975/pubmed\" target=\"_blank\" id=\"2014975\">2014975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halstenson CE, Wong MO, Herman CS, et al, &quot;Effect of Concomitant Administration of Piperacillin on the Dispositions on Isepamicin and Gentamicin in Patients With End-Stage Renal Disease,&quot; <i>Antimicrob Agents Chemother</i>, 1992, 36(9):1832-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/1416875/pubmed\" target=\"_blank\" id=\"1416875\">1416875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heinonen OP, Slone D, and Shapiro S, &quot;Birth Defects and Drugs in Pregnancy,&quot; Publishing Sciences Group, Inc, Littleton, MA, 1977.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Halilovic J, Christensen CL. Vancomycin-resistant enterococcal urinary tract infections. <i>Pharmacotherapy</i>. 2010;30(11):1136-1149.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/20973687/pubmed\" target=\"_blank\" id=\"20973687\">20973687</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hitt CM, Patel KB, Nicolau DP, et al, &quot;Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily,&quot; <i>Am J Health Syst Pharm</i>, 1997, 54(23):2704-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/9408514/pubmed\" target=\"_blank\" id=\"9408514\">9408514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jevsevar DS and Abt E, &quot;The New AAOS-ADA Clinical Practice Guideline on Prevention of Orthopaedic Implant Infection in Patients Undergoing Dental Procedures,&quot; <i>J Am Acad Orthop Surg</i>, 2013, 21(3):195-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/23457071/pubmed\" target=\"_blank\" id=\"23457071\">23457071</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jick H, Holmes LB, Hunter JR, et al, &quot;First-Trimester Drug Use and Congenital Disorders,&quot; <i>JAMA</i>, 1981, 246(4):343-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/7241780/pubmed\" target=\"_blank\" id=\"7241780\">7241780</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Konishi H, Goto M, Nakamoto Y, et al, &quot;Tobramycin Inactivation by Carbenicillin, Ticarcillin, and Piperacillin,&quot; <i>Antimicrob Agents Chemother</i>, 1983, 23(5):653-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/6223576/pubmed\" target=\"_blank\" id=\"6223576\">6223576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lau A, Lee M, Flascha S, et al, &quot;Effect of Piperacillin on Tobramycin Pharmacokinetics in Patients With Normal Renal Function,&quot; <i>Antimicrob Agents Chemother</i>, 1983, 24(4):533-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/6651279/pubmed\" target=\"_blank\" id=\"6651279\">6651279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lorber B. Listeriosis. <i>Clin Infect Dis</i>. 1997;24(1):1-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/8994747/pubmed\" target=\"_blank\" id=\"8994747\">8994747</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacAulay MA, Abou-Sabe M, and Charles D, &quot;Placental Transfer of Ampicillin,&quot;<i> Am J Obstet Gynecol</i>, 1966, 96(7):943-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/5928458/pubmed\" target=\"_blank\" id=\"5928458\">5928458</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Philipson A. Pharmacokinetics of ampicillin during pregnancy. <i>J Infect Dis</i>. 1977;136(3):370-376.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/903675/pubmed\" target=\"_blank\" id=\"903675\">903675</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Philipson A. Plasma levels of ampicillin in pregnant women following administration of ampicillin and pivampicillin. <i>Am J Obstet Gynecol</i>. 1978;130(6):674-683.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/637083 /pubmed\" target=\"_blank\" id=\"637083 \">637083 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Puh&oacute; EH, Szunyogh M, M&eacute;tneki J, et al, &quot;Drug Treatment During Pregnancy and Isolated Orofacial Clefts in Hungary,&quot; <i>Cleft Palate Craniofac J</i>, 2007, 44(2):194-202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/17328645/pubmed\" target=\"_blank\" id=\"17328645\">17328645</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Russoe ME and Atkins-Thor E, &quot;Gentamicin and Ticarcillin in Subjects With End-Stage Renal Disease. Comparison of Two Assay Methods and Evaluation of Inactivation Rate,&quot; <i>Clin Nephrol</i>, 1981, 15(4):175-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/7237864/pubmed\" target=\"_blank\" id=\"7237864\">7237864</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sollecito TP, Abt E, Lockhart PB, et al. The use of prophylactic antibiotics prior to dental procedures in patients with prosthetic joints: Evidence-based clinical practice guideline for dental practitioners--a report of the American Dental Association Council on Scientific Affairs. <i>J Am Dent Assoc.</i> 2015; 146(1):11-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/25569493/pubmed\" target=\"_blank\" id=\"25569493\">25569493</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Syed Q, Hendler KT, Koncilja K. The Impact of Aging and Medical Status on Dysgeusia. <i>Am J Med</i>. 2016;129(7):753.e1-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tenenbein M, Cohen S, and Sitar DS, &ldquo;Whole Bowel Irrigation as a Decontamination Procedure After Acute Drug Overdose,&rdquo; <i>Arch Intern Med</i>, 1987, 147(5):905-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/3579442/pubmed\" target=\"_blank\" id=\"3579442\">3579442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thompson MIB, Russo ME, Saxon BJ, et al, &quot;Gentamicin Inactivation by Piperacillin or Carbenicillin in Patients With End-Stage Renal Disease,&quot; <i>Antimicrob Agents Chemother</i>, 1982, 21(2):268-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/6462107/pubmed\" target=\"_blank\" id=\"6462107\">6462107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Triggs EJ, Johnson JM, and Learoyd B, &ldquo;Absorption and Disposition of Ampicillin in the Elderly,&rdquo; <i>Eur J Clin Pharmacol</i>, 1980, 18(2):195-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/7428803/pubmed\" target=\"_blank\" id=\"7428803\">7428803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Viollier AF, Standiford HC, Drusano GL, et al, &quot;Comparative Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin, Ticarcillin and Piperacillin, With and Without Gentamicin,&quot; <i>J Antimicrob Chemother</i>, 1985, 15(5):597-606.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/4008387/pubmed\" target=\"_blank\" id=\"4008387\">4008387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walterspiel JN, Feldman S, Van R, et al, &quot;Comparative Inactivation of Isepamicin, Amikacin, and Gentamicin by Nine Beta-Lactams and Two Beta-Lactamase Inhibitors, Cilastatin and Heparin,&quot; <i>Antimicrob Agents Chemother</i>, 1991, 35(9):1875-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/1952861/pubmed\" target=\"_blank\" id=\"1952861\">1952861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wasz-H&ouml;ckert O, Nummi S, Vuopala S, et al, &quot;Transplacental Passage of Azidocillin, Ampicillin and Penicillin G During Early and Late Pregnancy,&quot; <i>Acta Paediatr Scand Suppl</i>, 1970, 206(Suppl 206):109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/5276929/pubmed\" target=\"_blank\" id=\"5276929\">5276929</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo; <i>Circulation</i>, 2007, 115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/17446442/pubmed\" target=\"_blank\" id=\"17446442\">17446442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wright AJ, &ldquo;The Penicillins,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(3):290-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-drug-information/abstract-text/10090000/pubmed\" target=\"_blank\" id=\"10090000\">10090000</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8737 Version 199.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F134956\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F135006\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F134960\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F134982\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F134961\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F134962\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15673180\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F134931\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F134915\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F134935\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F134934\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475066\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F135014\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F134922\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F134938\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F134919\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298748\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F134924\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F134951\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F134927\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F134941\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5673664\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F134942\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F134929\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F134918\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F134937\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422187\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F134943\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8737|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ampicillin-patient-drug-information\" class=\"drug drug_patient\">Ampicillin: Patient drug information</a></li><li><a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">Ampicillin: Pediatric drug information</a></li></ul></div></div>","javascript":null}